<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00452439</url>
  </required_header>
  <id_info>
    <org_study_id>ID03-0124</org_study_id>
    <secondary_id>NCI-2010-01997</secondary_id>
    <nct_id>NCT00452439</nct_id>
  </id_info>
  <brief_title>A Study of Actonel for the Prevention of Bone Loss</brief_title>
  <official_title>A Randomized, Double Blinded Study of Actonel for the Prevention of Bone Loss in Patients Receiving High Dose Corticosteroids for the Treatment of Acute Lymphocytic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Procter and Gamble</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if Actonel (risedronate) can help to&#xD;
      prevent the development of osteoporosis (brittle and weak bones) caused by the steroid&#xD;
      medication used to treat leukemia. The safety of this treatment in patients with ALL or LL&#xD;
      will also be studied.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      One of the side effects of using high dose corticosteroids for the treatment of ALL is&#xD;
      osteoporosis. Risedronate is a medication that was designed to help prevent osteoporosis&#xD;
      (brittle and weak bones).&#xD;
&#xD;
      Before treatment you will receive a complete physical exam. You will have around 1 tablespoon&#xD;
      of blood drawn for blood tests (these tests are in addition to the routine blood tests you&#xD;
      will have as part of the treatment for leukemia). You will have a urine sample collected for&#xD;
      routine tests. You will also have a bone mineral density test. This test measures the density&#xD;
      of the bones in your spine, hip, and total body. The test is similar to having x-rays of your&#xD;
      bones taken.&#xD;
&#xD;
      You will be randomly assigned (as in the toss of a coin) to one of two treatment groups.&#xD;
      Participants in the first group will be given risedronate (once per week), vitamin D (once&#xD;
      per day), and calcium (once per day). All three medications are pills and will be taken by&#xD;
      mouth. Participants in the second group will be given placebo (once per week), vitamin D&#xD;
      (once per day), and calcium (once per day). All three medications are pills and will be taken&#xD;
      by mouth. A placebo is a substance that looks like the study drug but has no active&#xD;
      ingredients. Neither you nor your doctor will know to which group you are assigned. However,&#xD;
      if it is needed for your care, the information will be given to your doctor.&#xD;
&#xD;
      Participants in both groups will continue to receive chemotherapy during this study as&#xD;
      scheduled. During chemotherapy, you will have around 1 tablespoon of blood drawn every 1-2&#xD;
      weeks for routine blood tests (as part of the standard of care for your treatment of&#xD;
      leukemia).&#xD;
&#xD;
      For this study, you will have urine samples collected and repeat bone mineral density tests 6&#xD;
      months, 12 months, 18 months, and 24 months after starting the study drug (or placebo).&#xD;
&#xD;
      If you develop intolerable side effects from the risedronate you will be taken off the study.&#xD;
&#xD;
      This is an investigational study. Risedronate is FDA approved and commercially available. Up&#xD;
      to 80 eligible patients will take part in this study. All will be enrolled at M. D. Anderson.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone Loss Reduction: Mean Percent Changes in BMD for Each Treatment Arm at the 6 Months</measure>
    <time_frame>6 months</time_frame>
    <description>bone mineral density (BMD) Mean percent Change in Bone Density from Baseline to 6 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bone Loss Reduction: Mean Percent Changes in BMD for Each Treatment Arm at 12 Months</measure>
    <time_frame>12 months</time_frame>
    <description>bone mineral density (BMD) Mean percent Change in Bone Density from Baseline to 12 months</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Actonel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Actonel (Risedronate) + Vitamin D + Calcium</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo + Vitamin D + Calcium</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Actonel (Risedronate)</intervention_name>
    <description>35 mg (pill) by mouth weekly</description>
    <arm_group_label>Actonel</arm_group_label>
    <other_name>Risedronate Sodium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Calcium</intervention_name>
    <description>500 mg by mouth twice a day for a total of 24 months.</description>
    <arm_group_label>Actonel</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>400 IU by mouth twice a day for a total of 24 months.</description>
    <arm_group_label>Actonel</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age greater than or equal to 18 years&#xD;
&#xD;
          2. Newly diagnosed ALL or LL receiving chemotherapy with augmented BFM, Hyper-CVAD or any&#xD;
             variant of hyper-CVAD.&#xD;
&#xD;
          3. Female patients of childbearing potential (i.e. no hysterectomy, no loss of menses for&#xD;
             12 consecutive months), must be willing to use contraception.&#xD;
&#xD;
          4. Negative pregnancy test in female patients.&#xD;
&#xD;
          5. Patients must be enrolled within 6 weeks of starting induction chemotherapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hypocalcemia of less than 8.4 (corrected to account for the albumin level, [see&#xD;
             Appendix E for formula])&#xD;
&#xD;
          2. Hypersensitivity to risedronate or other bisphosphonates&#xD;
&#xD;
          3. Inability to sit or stand upright for at least 30 minutes&#xD;
&#xD;
          4. Bone density T-score of -2.5 S.D or less.&#xD;
&#xD;
          5. Renal insufficiency (calculated creatinine clearance &lt;30cc/min,[see Appendix F for&#xD;
             formula])&#xD;
&#xD;
          6. Patients with a 25-hydroxyvitamin D concentration of less than 20 ng/ml and evidence&#xD;
             of osteomalacia (low ionized calcium and high intact PTH).&#xD;
&#xD;
          7. Concomitant use of bisphosphonates, calcitonin, anabolic steroids, or fluoride.&#xD;
&#xD;
          8. Corrected calcium above 10.2, due to a cause not related to leukemia/lymphoma (i.e.&#xD;
             hyperparathyroidism, multiple myeloma).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria E. Cabanillas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>March 23, 2007</study_first_submitted>
  <study_first_submitted_qc>March 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2007</study_first_posted>
  <results_first_submitted>November 9, 2020</results_first_submitted>
  <results_first_submitted_qc>December 2, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 28, 2020</results_first_posted>
  <last_update_submitted>December 2, 2020</last_update_submitted>
  <last_update_submitted_qc>December 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leukemia</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Acute Lymphocytic Leukemia</keyword>
  <keyword>Lymphoblastic Lymphoma</keyword>
  <keyword>Actonel</keyword>
  <keyword>Risedronate</keyword>
  <keyword>Bone Loss</keyword>
  <keyword>Osteoporosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Risedronic Acid</mesh_term>
    <mesh_term>Etidronic Acid</mesh_term>
    <mesh_term>Calcium</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: February 06, 2004 to March 10, 2010. All participants were recruited at University of Texas (UT) MD Anderson Cancer Center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Actonel</title>
          <description>Actonel (Risedronate) + Vitamin D + Calcium&#xD;
Actonel 35 mg orally weekly, Calcium 500 mg orally twice a day, and Vitamin D 400 IU orally twice a day for a total of 24 months.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo + Vitamin D + Calcium&#xD;
Placebo weekly, Calcium 500 mg orally twice a day, and Vitamin D 400 IU orally twice a day for a total of 24 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refused Treatment</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Bone Marrow Transplant</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Too Ill to Continue</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failed to achieve complete response</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Relapse</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Fracture</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Actonel</title>
          <description>Actonel (Risedronate) + Vitamin D + Calcium&#xD;
Actonel 35 mg orally weekly, Calcium 500 mg orally twice a day, and Vitamin D 400 IU orally twice a day for a total of 24 months.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo + Vitamin D + Calcium&#xD;
Placebo weekly, Calcium 500 mg orally twice a day, and Vitamin D 400 IU orally twice a day for a total of 24 months.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="36"/>
            <count group_id="B2" value="36"/>
            <count group_id="B3" value="72"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29" lower_limit="23" upper_limit="49"/>
                    <measurement group_id="B2" value="42" lower_limit="26" upper_limit="53"/>
                    <measurement group_id="B3" value="36" lower_limit="23" upper_limit="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Bone Loss Reduction: Mean Percent Changes in BMD for Each Treatment Arm at the 6 Months</title>
        <description>bone mineral density (BMD) Mean percent Change in Bone Density from Baseline to 6 months.</description>
        <time_frame>6 months</time_frame>
        <population>Of 72 randomized, 22 participants in risedronate &amp; 29 in placebo had at least a 6-month follow-up bone mineral density and were considered evaluable for the primary endpoint. Only 12/22 patients (55%) in risedronate and 7/29 patients (24%) in the placebo arm had 12 month DXA scan performed, mostly due to significant decreases in bone density.</population>
        <group_list>
          <group group_id="O1">
            <title>Actonel</title>
            <description>Actonel (Risedronate) + Vitamin D + Calcium&#xD;
Actonel 35 mg orally weekly, Calcium 500 mg orally twice a day, and Vitamin D 400 IU orally twice a day for a total of 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo + Vitamin D + Calcium&#xD;
Placebo weekly, Calcium 500 mg orally twice a day, and Vitamin D 400 IU orally twice a day for a total of 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Loss Reduction: Mean Percent Changes in BMD for Each Treatment Arm at the 6 Months</title>
          <description>bone mineral density (BMD) Mean percent Change in Bone Density from Baseline to 6 months.</description>
          <population>Of 72 randomized, 22 participants in risedronate &amp; 29 in placebo had at least a 6-month follow-up bone mineral density and were considered evaluable for the primary endpoint. Only 12/22 patients (55%) in risedronate and 7/29 patients (24%) in the placebo arm had 12 month DXA scan performed, mostly due to significant decreases in bone density.</population>
          <units>Percent of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lumbar Spine 6 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" spread="0.05"/>
                    <measurement group_id="O2" value="-3.5" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Hip 6 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.6" spread="0.06"/>
                    <measurement group_id="O2" value="-11" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Hip 6 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.2" spread="0.06"/>
                    <measurement group_id="O2" value="-11" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Bone Loss Reduction: Mean Percent Changes in BMD for Each Treatment Arm at 12 Months</title>
        <description>bone mineral density (BMD) Mean percent Change in Bone Density from Baseline to 12 months</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Actonel</title>
            <description>Actonel (Risedronate) + Vitamin D + Calcium&#xD;
Actonel 35 mg orally weekly, Calcium 500 mg orally twice a day, and Vitamin D 400 IU orally twice a day for a total of 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo + Vitamin D + Calcium&#xD;
Placebo weekly, Calcium 500 mg orally twice a day, and Vitamin D 400 IU orally twice a day for a total of 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Loss Reduction: Mean Percent Changes in BMD for Each Treatment Arm at 12 Months</title>
          <description>bone mineral density (BMD) Mean percent Change in Bone Density from Baseline to 12 months</description>
          <units>percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lumbar Spine 12 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="0.05"/>
                    <measurement group_id="O2" value="-5" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Hip 12 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.8" spread="0.05"/>
                    <measurement group_id="O2" value="-5.8" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Hip 12 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.1" spread="0.05"/>
                    <measurement group_id="O2" value="-7" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 6 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Actonel</title>
          <description>Actonel (Risedronate) + Vitamin D + Calcium&#xD;
Actonel 35 mg orally weekly, Calcium 500 mg orally twice a day, and Vitamin D 400 IU orally twice a day for a total of 24 months.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo + Vitamin D + Calcium&#xD;
Placebo weekly, Calcium 500 mg orally twice a day, and Vitamin D 400 IU orally twice a day for a total of 24 months.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Maria Cabanillas, Associate Professor, Endocrine Neoplasia and HD</name_or_title>
      <organization>University of Texas (UT) MD Anderson Cancer Center</organization>
      <phone>(713) 563-0764</phone>
      <email>mcabani@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

